Hodgkin's disease.
Despite incomplete understanding of the etiology of Hodgkin's disease and its malignant cell of origin, the majority of children and adolescents diagnosed with Hodgkin's disease will be longterm survivors. Staging and treatment for pediatric Hodgkin's disease has evolved over the past 30 years in attempts to reduce late treatment sequelae. Today, most children are clinically staged and treated with multitreatment chemotherapy, either alone or in conjunction with low-dose, involved field radiation therapy. Initial results with "risk-adapted" combined modality regimens limiting chemotherapy cycles and radiation doses and volumes demonstrate maintenance of cure rates for early stage, favorable Hodgkin's disease. Challenges for the future include identification of prognostic factors in patients at risk for treatment failure who may benefit from intensification of therapy.
Hudson
M M
MM
Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Donaldson
S S
SS
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D003131:Combined Modality Therapy; D003952:Diagnostic Imaging; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D009367:Neoplasm Staging